Literature DB >> 12162935

Specialized lipid profiles.

Karen E Friday1.   

Abstract

Individuals with abnormal blood lipids and lipoproteins are at increased risk for cardiovascular disease. With the development of effective dietary, behavioral, and pharmaceutical treatments to optimize blood lipoproteins, accurate clinical assessment of blood lipids and lipoproteins are essential for patient management and research. This article discusses the use of a variety of lipid analyses currently available. The use of traditional lipoprotein measurements, including Friedewald calculation of low-density lipoprotein (LDL) cholesterol and ultracentrifugation methods to measure blood lipoproteins, are discussed. Newer analytic techniques, including the vertical analytic profile, nuclear magnetic resonance, direct LDL measurement, LDL size determination, and triglyceride-rich lipoprotein remnants, are also described. Despite the development of a number of lipid and lipoprotein assays, lipoprotein analysis with a Friedewald- calculated LDL measurement remains the lipoprotein analysis performed in approximately 93% of clinical laboratories. It remains to be determined if the alternative lipid and lipoprotein assays currently available will become more widely utilized in the future.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162935     DOI: 10.1007/s11883-002-0073-8

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  22 in total

1.  Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes.

Authors:  K E Friday; C Dong; R U Fontenot
Journal:  J Clin Endocrinol Metab       Date:  2001-01       Impact factor: 5.958

2.  Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy.

Authors:  J D Otvos; E J Jeyarajah; D W Bennett
Journal:  Clin Chem       Date:  1991-03       Impact factor: 8.327

3.  Inaccuracy of lipid measurements with the portable Cholestech L.D.X analyzer in patients with hypercholesterolemia.

Authors:  James H Stein; Cynthia M Carlsson; Kristi Papcke-Benson; Jean A Einerson; Patrick E McBride; Donald A Wiebe
Journal:  Clin Chem       Date:  2002-02       Impact factor: 8.327

4.  Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial.

Authors:  James D Otvos; Irina Shalaurova; David S Freedman; Robert S Rosenson
Journal:  Atherosclerosis       Date:  2002-01       Impact factor: 5.162

5.  Levels and correlates of LDL and VLDL particle sizes among children: the Bogalusa heart study.

Authors:  D S Freedman; B A Bowman; J D Otvos; S R Srinivasan; G S Berenson
Journal:  Atherosclerosis       Date:  2000-10       Impact factor: 5.162

6.  Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides.

Authors:  F Karpe; S Boquist; R Tang; G M Bond; U de Faire; A Hamsten
Journal:  J Lipid Res       Date:  2001-01       Impact factor: 5.922

7.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

8.  Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia.

Authors:  D T Stein; S Devaraj; D Balis; B Adams-Huet; I Jialal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-12       Impact factor: 8.311

9.  Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.

Authors:  J H Stein; M A Klein; J L Bellehumeur; P E McBride; D A Wiebe; J D Otvos; J M Sosman
Journal:  Circulation       Date:  2001-07-17       Impact factor: 29.690

10.  Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease.

Authors:  D S Freedman; J D Otvos; E J Jeyarajah; J J Barboriak; A J Anderson; J A Walker
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-07       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.